Calgary, Alberta, September 4, 2025 – TheNewswire - Universal Ibogaine Inc. (TSXV: IBO, in USA: IBOGF, in Germany FSE:JC4)  (“UI” or the “Company) is pleased to announce its intention to file, within 90 days, an application to Health Canada to initiate clinical trials (the Clinical Trial Application, or “CTA”) with the aim of investigating Ibogaine as a promising treatment for addiction for opioid use disorder(s) (the “Trial”). In addition, the Company has secured a reliable and compliant supply of pha ...

 Calgary, AB – September 3, 2025 – TheNewswire - Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that the existing Board of Directors of the Company (the “Board”) appointed two new Directors to join the Board, effective August 28, 2025, with one of the Board members filling a vacant Board position which previously arose in July 2025.The two new Board members are Nia Killebrew and ...